{"id":1022125,"date":"2026-11-18T02:03:20","date_gmt":"2026-11-18T07:03:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/"},"modified":"2026-11-18T02:03:20","modified_gmt":"2026-11-18T07:03:20","slug":"nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/","title":{"rendered":"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"right\">\n        <b>INSIDE INFORMATION<\/b><br \/>\n        <br \/>\n        <b>REGULATED INFORMATION<\/b>\n      <\/p>\n<p align=\"center\">\n        <b>Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case<\/b>\n      <\/p>\n<p align=\"justify\">\n        <b>Mont-Saint-Guibert, Belgium \u2013 November 18, 2026, 8:00 am CET \/ 2:00 am ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/b> (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC) in Munich, Germany, issued a decision by default in favor of Nyxoah. Nyxoah had filed an infringement case against Inspire Medical Systems at the UPC regarding Nyxoah\u2019s European Patent 2 760 534. <\/p>\n<p align=\"justify\">Nyxoah is currently considering all options of enforcement.<\/p>\n<p align=\"justify\">\n        <b>About Nyxoah<\/b>\n      <\/p>\n<p align=\"justify\">Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah\u2019s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n<p align=\"justify\">Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uHxlz7Jw87xDuc0XYglFFy_xDZrXi7PFjhFUmSaVlWL-5nhbrsn_9pOdcFiDTM3Ldt2ZCRBTkfif0aeMV00Cevor4Kjx5_TJZ2Co6UAnbzY=\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.nyxoah.com<\/a>.<\/p>\n<p align=\"justify\">Caution \u2013 CE marked since 2019. FDA approved in August 2025 as prescription-only device.<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statements<\/b>\n      <\/p>\n<p align=\"justify\">Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company\u2019s or, as appropriate, the Company directors\u2019 or management\u2019s current expectations regarding the Genio system; the final outcome of any lawsuit or legal procedure between Nyxoah and Inspire Medical Systems; the potential advantages of the Genio system; Nyxoah\u2019s goals with respect to the potential use of the Genio system; the PMA supplement to the FDA and the timing and outcome of any FDA review; the Company&#8217;s commercialization strategy and growth in the U.S. market; the Company&#8217;s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person&#8217;s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.<\/p>\n<p align=\"justify\">\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <b>Nyxoah<\/b><br \/>\n        <br \/>Lo\u00efc Moreau, Interim CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bmZiqde7HsSK5iTd4a3AqxlI2rCnIlu5sQY1_UKOSPCReukRVDQmPk3GOEGV_j0f5G7CCWrIAUQSQv-2cz770g==\" rel=\"nofollow\" target=\"_blank\">IR@nyxoah.com<\/a><\/p>\n<p>R\u00e9mi Renard, Head of Investor Relations &amp; Corporate Communication<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bmZiqde7HsSK5iTd4a3Aq0aK-EfQmGx3mW3LVQTh_74R2qgAXlIo0JWT0INWf4PiUHLcZgqawODhafJ3ils-2g==\" rel=\"nofollow\" target=\"_blank\">IR@nyxoah.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/ce9354f0-3c13-4b61-af64-68514bfa0b39\">ENGLISH_PR Default decision_FINAL<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MzUyMjMyODYtNzczNy00YmNkLWE3NGItOWE1MGMwZTA5Y2Q0LTEyMDkxODAtMjAyNi0xMS0xOC1lbg==\/tiny\/Nyxoah.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>INSIDE INFORMATION REGULATED INFORMATION Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case Mont-Saint-Guibert, Belgium \u2013 November 18, 2026, 8:00 am CET \/ 2:00 am ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH) (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC) in Munich, Germany, issued a decision by default in favor of Nyxoah. Nyxoah had filed an infringement case against Inspire Medical Systems at the UPC regarding Nyxoah\u2019s European Patent 2 760 534. Nyxoah is currently considering all options of enforcement. About Nyxoah Nyxoah is a medical technology company focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022125","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"INSIDE INFORMATION REGULATED INFORMATION Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case Mont-Saint-Guibert, Belgium \u2013 November 18, 2026, 8:00 am CET \/ 2:00 am ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH) (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC) in Munich, Germany, issued a decision by default in favor of Nyxoah. Nyxoah had filed an infringement case against Inspire Medical Systems at the UPC regarding Nyxoah\u2019s European Patent 2 760 534. Nyxoah is currently considering all options of enforcement. About Nyxoah Nyxoah is a medical technology company focused on &hellip; Continue reading &quot;Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T07:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case\",\"datePublished\":\"2026-11-18T07:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/\"},\"wordCount\":822,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/\",\"name\":\"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==\",\"datePublished\":\"2026-11-18T07:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/","og_locale":"en_US","og_type":"article","og_title":"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case - Market Newsdesk","og_description":"INSIDE INFORMATION REGULATED INFORMATION Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case Mont-Saint-Guibert, Belgium \u2013 November 18, 2026, 8:00 am CET \/ 2:00 am ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH) (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC) in Munich, Germany, issued a decision by default in favor of Nyxoah. Nyxoah had filed an infringement case against Inspire Medical Systems at the UPC regarding Nyxoah\u2019s European Patent 2 760 534. Nyxoah is currently considering all options of enforcement. About Nyxoah Nyxoah is a medical technology company focused on &hellip; Continue reading \"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-18T07:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case","datePublished":"2026-11-18T07:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/"},"wordCount":822,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/","name":"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==","datePublished":"2026-11-18T07:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwNDE3OSM0MDI1NjU1ODAjMjE5NzYyNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-unified-patent-court-case\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022125"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022125\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}